ArticleFrontiers in cardiovascular medicine2026
Pharmaceutical stability of compounded acetylcholine chloride intraocular solution for intracoronary provocative vasospasm testing.
Article in Frontiers in cardiovascular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Provocative coronary vasospasm testing requires intracoronary acetylcholine (ACh) administration, however an ACh drug formulation approved for intracoronary use is not commercially available. Invasive coronary vasomotor testing programs have thus resorted to reconstituting and diluting ophthalmic ACh solutions for off-label and off-target intracoronary use, despite a lack of comprehensive ACh stability testing data required by pharmacy compounding regulations USP <797 > . This study aims to characterize the stability of compounded ACh intraocular solutions according to current pharmacy guidelines for use in provocative intracoronary ACh vasospasm testing. Methods: Potency and stability testing was performed by an FDA and DEAS registered, A2LA ISO 17025:2017 accredited laboratory. Using a simple, 7-step compounding method, a single vial of intraocular ACh solution was reconstituted and diluted with 500 mL of dextrose 5% water (D5W) to a final concentration of 18.2 mcg/mL. Compounded ACh was then stored in 20 mL syringes at ambient room temperature (25 ± 2 °C and 60 ± 5% relative humidity) under normal fluorescent lighting to simulate routine cardiac catheterization laboratory conditions. The compounded ACh solution appearance, pH, particulate matter, concentration and potency were evaluated in triplicate at 0, 4, and 12 h after compounding. Results: The compounded ACh solution was clear and colorless with a pH of 4.2 across all time points. Subvisible particulate matter, assessed by light obscuration techniques, demonstrated that the quantity of >10 Conclusion: Utilizing a novel compounding method, intraocular ACh reconstituted and diluted in D5W met all USP <797 > pharmacy stability regulatory criteria over 12 h under ambient room temperature storage conditions. This study thus establishes a simplified ACh compounding approach for invasive coronary function testing centers to generate an intracoronary ACh drug formulation for use within 12 h in provocative coronary vasospasm testing procedures.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.